Ho A D, Schwarz C E, Hunstein W
Leuk Res. 1985;9(10):1293-8. doi: 10.1016/0145-2126(85)90159-6.
Patients with acute myeloid leukemia (AML) secondary to myelodysplastic phase respond poorly to standard chemotherapy designed for AML. As arabinosyl cytosine (Ara-C) at low-dose has been reported to achieve promising results in certain forms of AML, we have applied the low-dose (10 mg m-2/12 h subcutaneously for 14-24 days) regimen in 11 patients with AML secondary to myelodysplastic syndromes. Though a complete remission could be achieved in 2 patients and a short partial remission in 2 further patients, complications are severe and often life threatening. The amount of hematological supportive care required often exceeded that needed for patients treated by conventional TAD regimen. Moreover, survival of the responders did not seem to be longer than that of non-responders. A review of the literature showed that the results of this low-dose Ara-C regimen might be more promising in patients in the myelodysplastic phase and in those with de novo acute leukemia.
继发于骨髓增生异常阶段的急性髓系白血病（AML）患者对针对AML设计的标准化疗反应不佳。由于据报道低剂量阿糖胞苷（Ara-C）在某些形式的AML中取得了有前景的结果，我们对11例继发于骨髓增生异常综合征的AML患者应用了低剂量方案（10 mg/m²，皮下注射，每12小时一次，共14 - 24天）。尽管2例患者实现了完全缓解，另有2例患者实现了短期部分缓解，但并发症严重且常危及生命。所需的血液学支持治疗量常常超过接受传统TAD方案治疗的患者。此外，有反应者的生存期似乎并不比无反应者更长。文献综述表明，这种低剂量Ara-C方案在处于骨髓增生异常阶段的患者以及初发急性白血病患者中可能更有前景。
